File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Pharmacological treatments prescribed to young people with autism spectrum disorder (ASD) in UK primary care

TitlePharmacological treatments prescribed to young people with autism spectrum disorder (ASD) in UK primary care
Authors
Keywordsautism spectrum disorder
psychotropic drugs
co-morbidities
prevalence
Issue Date2013
PublisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62
Citation
The 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 142 How to Cite?
AbstractAims/Objective: Little is known about patterns of pharmacological treatment and associated co-morbidities in ASD. We assessed the prevalence of ASD, psychotropic drug prescribing and neuropsychiatric co-morbidities in young people. Methods: A descriptive cohort study using The Health Improvement Network database of UK patient records. Individuals aged <25 years with a diagnosis of ASD during 1992-2008 were identifi ed. Annual ASD prevalence and proportions of the cohort prescribed psychotropic medications or with neuropsychiatric co-morbidities were calculated. Results: Psychotropic drugs were prescribed to 29% (1,619/5,651) of the cohort; the most prescribed drugs were sleep medication (9.7%), psychostimulants (7.9%), antipsychotics (7.3%). Psychostimulant prescribing increased from 1.5% to 6.3% (1999 to 2008). Neuropsychiatric co-morbidities were seen in 37% of patients; developmental diffi culties/learning disability were most common (12.6%). Conclusions: Use of psychostimulants and antipsychotics is much higher in those with ASD than in the general population. Further studies examining their effi cacy and long-term safety are needed.
DescriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia
Oral Presentation - Paediatrics – Mental and General Health
Persistent Identifierhttp://hdl.handle.net/10722/204454
ISSN

 

DC FieldValueLanguage
dc.contributor.authorMurray, MLen_US
dc.contributor.authorHsia, YFen_US
dc.contributor.authorGlaser, Ken_US
dc.contributor.authorSimonoff, Een_US
dc.contributor.authorMurphy, DGMen_US
dc.contributor.authorAsherson, PJen_US
dc.contributor.authorEklund, Hen_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2014-09-19T23:52:22Z-
dc.date.available2014-09-19T23:52:22Z-
dc.date.issued2013en_US
dc.identifier.citationThe 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 142en_US
dc.identifier.issn1727-2874-
dc.identifier.urihttp://hdl.handle.net/10722/204454-
dc.descriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia-
dc.descriptionOral Presentation - Paediatrics – Mental and General Health-
dc.description.abstractAims/Objective: Little is known about patterns of pharmacological treatment and associated co-morbidities in ASD. We assessed the prevalence of ASD, psychotropic drug prescribing and neuropsychiatric co-morbidities in young people. Methods: A descriptive cohort study using The Health Improvement Network database of UK patient records. Individuals aged <25 years with a diagnosis of ASD during 1992-2008 were identifi ed. Annual ASD prevalence and proportions of the cohort prescribed psychotropic medications or with neuropsychiatric co-morbidities were calculated. Results: Psychotropic drugs were prescribed to 29% (1,619/5,651) of the cohort; the most prescribed drugs were sleep medication (9.7%), psychostimulants (7.9%), antipsychotics (7.3%). Psychostimulant prescribing increased from 1.5% to 6.3% (1999 to 2008). Neuropsychiatric co-morbidities were seen in 37% of patients; developmental diffi culties/learning disability were most common (12.6%). Conclusions: Use of psychostimulants and antipsychotics is much higher in those with ASD than in the general population. Further studies examining their effi cacy and long-term safety are needed.-
dc.languageengen_US
dc.publisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62-
dc.relation.ispartofHong Kong Pharmaceutical Journalen_US
dc.subjectautism spectrum disorder-
dc.subjectpsychotropic drugs-
dc.subjectco-morbidities-
dc.subjectprevalence-
dc.titlePharmacological treatments prescribed to young people with autism spectrum disorder (ASD) in UK primary careen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.identifier.hkuros239881en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage142en_US
dc.identifier.epage142en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats